招商证券国际发表研报指，中国生物制药上半年收入按年增10%，达176亿元，超预期。管理层指引下半年增长提速，该行预计公司2026及27年将恢复双位数增长，又认为呼吸系统及肝病领域的增长潜力被市场低估，因公司有更优的增长前景与丰富的商业发展(BD)机会，将公司目标价上调至9.8港元，维持“增持”评级。 该行对中生制药持乐观看法，认为其作为行业领导者受益于肿瘤及外科、镇痛药物的强劲表现，以及集中采购政策稳定对均价的负面影响减弱。公司过去通过有效的资产处置，重新聚焦四大治疗领域，该行预计这将提升整体的经验效率和质量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.